BLFS

Total revenue of $28.5 million, up 21% over Q2 2025 GAAP gross margin of 64% and non-GAAP adjusted gross margin of 65% GAAP net income of $45.1 million, inclusive of a $42.4 million non-cash income tax benefit, and non-GAAP adjusted EBITDA of $7.4 million, or 26% of revenue Repligen to acquire BioLife and the proposed transaction is expected to close in the fourth quarter of 2026 BOTHELL, Wash., Aug. 6, 2026 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene therapy ("CGT") market, announces financial results for the three and six months ended June 30, 2026. "We delivered another strong quarter, with solid execution across the business led by our market-leading biopreservation media franchise," said Roderick de Greef, Chairman and Chief Executive Officer of BioLife. "This continued performance underscores the important role our technologies play in enabling the advancement of cell and gene therapies. We look forward to building on this foundation through our announced combination with Repligen, which is expected to close in the fourth quarter of 2026." Second Quarter 2026 Business Highlights On July 21, 2026, BioLife entered into a definitive agreement under which Repligen, subject to customary closing conditions, will acquire BioLife for a total enterprise value of approximately $1.5 billion, comprised of $11.25 cash and 0.1442 shares of Repligen's common stock, on a per share basis of BioLife's common stock. As a result of the merger, BioLife will cease to be a publicly traded company. The transaction is expected to close in the fourth quarter of 2026, subject to approval by BioLife stockholders, regulatory approvals and other customary closing conditions. Our biopreservation media is utilized in approximately 250 ongoing commercially sponsored clinical trials in the U.S., representing a more than 70% market share. This includes over 30 Phase III trials, or nearly 80% of these late-stage trials. Our CellSeal vials and hPL products are used in over 35 clinical trials. Our biopreservation media is embedded in 18 unique commercial CGTs as of June 30, 2026, with expectations that approvals for 8 additional products, geographic expansions, earlier lines of treatment, or new indications will occur over the next 12 months. Our CellSeal cryogenic vials and hPL products are embedded in four approved therapies. Second Quarter 2026 Financial Results BioLife is presenting various financial metrics under U.S. generally accepted accounting principles (GAAP) and as adjusted (non-GAAP). In addition, BioLife completed the divestiture of evo in 2025, and is presenting its financial condition and operating results as discontinued operations for all periods presented within the Unaudited Condensed Consolidated Balance Sheets and Unaudited Condensed Consolidated Statements of Operations. The Unaudited Condensed Consolidated Statements of Comprehensive Income (Loss) and Unaudited Condensed Consolidated Statements of Cash Flows are presented on a consolidated basis for both continuing operations and discontinued operations. All amounts, percentages, and disclosures for all periods presented reflect only the continuing operations of the Company unless otherwise noted. REVENUE Total revenue for the second quarter of 2026 was $28.5 million, an increase of $5.0 million, or 21%, from $23.4 million for the second quarter of 2025 and up $1.0 million, or 4%, from the first quarter of 2026. Total revenue for the six months ended June 30, 2026 was $56.0 million, an increase of $10.5 million, or 23%, from $45.5 million for the six months ended June 30, 2025. GROSS MARGIN Gross margin (GAAP) for the second quarter of 2026 was 64% compared with 65% for the second quarter of 2025. Adjusted gross margin (non-GAAP) for the second quarter of 2026 was 65% compared with 66% for the second quarter of 2025. Gross margin (GAAP) for the six months ended June 30, 2026 was 64% compared with 66% for the six months ended June 30, 2025. Adjusted gross margin (non-GAAP) for the six months ended June 30, 2026 was 65% compared with 67% for the six months ended June 30, 2025. OPERATING INCOME / (LOSS) Operating income (GAAP) for the second quarter of 2026 was $1.7 million compared with an operating loss of $16.1 million for the second quarter of 2025. Adjusted operating income (non-GAAP) for the second quarter of 2026 was $3.1 million compared with an adjusted operating loss of $0.3 million for the second quarter of 2025. Operating income (GAAP) for the six months ended June 30, 2026 was $1.7 million compared with an operating loss of $16.6 million for the six months ended June 30, 2025. Adjusted operating income (non-GAAP) for the six months ended June 30, 2026 was $4.1 million compared with $0.9 million for the six months ended June 30, 2025. NET INCOME / (LOSS) Net income (GAAP) for the second quarter of 2026 was $45.1 million compared with a net loss of $15.3 million for the second quarter of 2025. Adjusted net income (non-GAAP) for the second quarter of 2026 was $4.2 million compared with $0.6 million for the second quarter of 2025. Due to the release of our valuation allowance during the second quarter of 2026, we recognized a non-cash income tax benefit of $42.4 million. Net income (GAAP) for the six months ended June 30, 2026 was $46.3 million compared with a net loss of $15.1 million for the six months ended June 30, 2025. Adjusted net income (non-GAAP) for the six months ended June 30, 2026 was $6.3 million compared with $2.6 million for the six months ended June 30, 2025. NET INCOME / (LOSS) PER SHARE Net income per share (GAAP) for the second quarter of 2026 was $0.92 compared with net loss per share of $0.32 for the second quarter of 2025. The release of our valuation allowance during the second quarter of 2026 had an $0.87 impact on our net income per share. Net income per share (GAAP) for the six months ended June 30, 2026 was $0.95 compared with net loss per share of $0.31 for the six months ended June 30, 2025. The release of our valuation allowance during the six months ended June 30, 2026 had an $0.87 impact on our income per share. ADJUSTED EBITDA Adjusted EBITDA, a non-GAAP measure, for the second quarter of 2026 was $7.4 million, or 26% of revenue, compared with $5.6 million, or 24% of revenue, for the second quarter of 2025. Adjusted EBITDA, a non-GAAP measure, for the six months ended June 30, 2026 was $13.5 million, or 24% of revenue, compared with $11.0 million, or 24% of revenue, for the six months ended June 30, 2025. CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES Cash, cash equivalents, and marketable securities as of June 30, 2026 were $113.1 million. Conference Call & Webcast Due to the pending acquisition of BioLife by Repligen, BioLife will not be hosting a conference call. About BioLife Solutions BioLife is a leading developer and supplier of cell processing tools and services for the CGT market. Our expertise facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during the collection, development, manufacturing and distribution. For more information, please visit www.biolifesolutions.com, and follow BioLife on LinkedIn and X. Cautions Regarding Forward Looking Statements Certain statements contained in this press release are not historical facts and may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "plans," "expects," "believes," "anticipates," "designed," "may," "estimate," "guidance," and similar words are intended to identify forward-looking statements. Forward-looking statements are based on our current expectations and beliefs, and involve a number of risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those stated or implied by the forward-looking statements. A description of certain of these risks, uncertainties and other matters can be found in filings we make with the U.S. Securities and Exchange Commission, all of which are available at www.sec.gov. Because forward-looking statements involve risks and uncertainties, actual results and events may differ materially from results and events currently expected by us. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We undertake no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in its expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Non-GAAP Measures of Financial Performance To supplement our financial statements, which are presented on the basis of U.S. generally accepted accounting principles (GAAP), the following non-GAAP measures of financial performance are included on a consolidated basis in this release: adjusted gross margin, adjusted operating expenses, adjusted operating income/(loss), adjusted net income/(loss), earnings before interest, taxes, depreciation and amortization (EBITDA), and adjusted EBITDA. A reconciliation of GAAP to adjusted non-GAAP financial measures is included as an attachment to this press release. We believe these non-GAAP financial measures are useful to investors in assessing our operating performance. We use these financial measures internally to evaluate our operating performance and for planning and forecasting of future periods. We also believe it is in the best interests of investors to provide this non-GAAP information. While we believe these non-GAAP financial measures provide useful supplemental information to investors, there are limitations associated with the use of these non-GAAP financial measures. These non-GAAP financial measures may not be reported by competitors, and they may not be directly comparable to similarly titled measures of other companies due to differences in calculation methodologies. The non-GAAP financial measures are not an alternative to GAAP information and are not meant to be considered in isolation or as a substitute for comparable GAAP financial measures. They should be used only as a supplement to GAAP information and should be considered only in conjunction with our consolidated financial statements prepared in accordance with GAAP. Media & Investor Relations At the Company Troy WichtermanChief Financial Officer(425) [email protected] John GrazianoInvestor [email protected] Investors Alliance Advisors IRVivian Cervantes(973) [email protected] View original content to download multimedia:https://www.prnewswire.com/news-releases/biolife-solutions-reports-second-quarter-2026-financial-results-302845351.html

BioLife Solutions, Inc. (BLFS) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to break-even earnings per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +500.00%. A quarter ago, it was expected that this company would post earnings of $0.01 per share when it actually produced earnings of $0.04, delivering a surprise of +300%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. BioLife Solutions, which belongs to the Zacks Medical - Products industry, posted revenues of $28.47 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 1.48%. This compares to year-ago revenues of $25.42 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. BioLife Solutions shares have added about 39.8% since the beginning of the year versus the S&P 500's gain of 12.8%. While BioLife Solutions has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for BioLife Solutions was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.01 on $29.03 million in revenues for the coming quarter and $0.03 on $114.38 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the bottom 37% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Another stock from the same industry, Agilent Technologies (A), has yet to report results for the quarter ended July 2026. The results are expected to be released on August 26. This scientific instrument maker is expected to post quarterly earnings of $1.48 per share in its upcoming report, which represents a year-over-year change of +8%. The consensus EPS estimate for the quarter has been revised 0.2% higher over the last 30 days to the current level. Agilent Technologies' revenues are expected to be $1.84 billion, up 6% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report BioLife Solutions, Inc. (BLFS) : Free Stock Analysis Report Agilent Technologies, Inc. (A) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Interested in BioLife Solutions, Inc.? Here are five stocks we like better. Q1 2026 results: Revenue was $27.5 million, up 25% year‑over‑year, with adjusted EBITDA of $6.2 million (22% of revenue); management reiterated full‑year 2026 guidance of $112.5–$115.0 million and expects to generate full‑year GAAP net income. BPM drives the business: Biopreservation media (BPM) represents over 85% of total revenue, with the top 20 BPM customers providing ~80% of BPM sales; products are embedded in 17 approved therapies with visibility into nine more and used in 250+ commercial CGT trials, giving strong demand visibility. Bag yield issues pressured margins: Manufacturing yields on bag formats reduced gross margins (adjusted gross margin ~64%), and the company is rolling out alternative configurations (including a rigid container concept) and expects margin improvement to begin in “either Q4 or Q1 of 2027” as inventory is burned through. Best Biotech Stocks to Invest in Now BioLife Solutions (NASDAQ:BLFS) reported first-quarter 2026 revenue of $27.5 million, up 25% year-over-year, as management pointed to continued strength in its biopreservation media (BPM) franchise and growing contribution from its broader cell processing tools portfolio. CEO and Chairman Roderick de Greef said the company is “off to a solid start to 2026,” with adjusted EBITDA rising about 15% from the prior year to $6.2 million, or 22% of revenue. He attributed the results to “continued strength across our broader product portfolio, led by our biopreservation media or BPM franchise,” and said BioLife’s simplified business and focus on “high margin recurring revenue” is creating operating leverage. → Berkshire Hathaway’s Record Cash Hoard: Why and What's Next? 3 Small-Cap Medical Stocks Moving Markets Today De Greef said BPM remains BioLife’s largest business, representing “over 85% of total revenue.” He added that BioLife’s top 20 BPM customers accounted for about 80% of BPM revenue, and that demand forecasts from these accounts provide “good visibility” into the business. Channel mix was described as consistent, with “over 60% of BPM revenue generated through direct sales with the balance through third-party distributors.” De Greef also noted that roughly half of BPM revenue came from customers with approved commercial therapies, which he characterized as a key contributor to durability because later-stage and commercial programs are “more stable” and “less sensitive to funding dynamics.” He said several supported therapies are already at or tracking toward blockbuster status, adding that BioLife expects to benefit as these therapies scale into new geographies and indications. → A Prada Payday: Is AMC Back in Style? On market penetration, de Greef said that at quarter-end BioLife’s BPM products were embedded in 17 approved therapies, with “visibility into an additional 9 unique approvals, expanded indications, and geographic expansions over the next 12 months.” He also estimated BioLife’s solutions are used in “more than 250 commercially sponsored CGT clinical trials in the U.S.,” representing more than 70% share and an even higher share in phase III programs. Management again flagged manufacturing yield issues affecting bag formats. De Greef said gross margin and adjusted EBITDA margin declined year-over-year due to “previously discussed bag yield dynamics,” calling it a key operational priority and expressing confidence the issue is “temporary in nature.” → Insider Sales: Top AST SpaceMobile Insider Cuts Postion Over 30% CFO Troy Wichterman reported GAAP gross margin of 64% in Q1 2026 versus 67% a year earlier, while adjusted gross margin was 64% versus 68% in the prior year. He said the decrease primarily reflected a mix shift toward bags, which have lower gross margins than bottles, and the impact from manufacturing yields. During the Q&A, Wichterman told Jefferies analyst Matt Stanton that “bags do have a lower gross margin than bottles by quite a bit at this point in time because of that yield issue.” He added margins should be “closer” once yields are rectified. De Greef said BioLife has been working with customers for the past 60 days on alternatives to the existing bag configuration. He said customer notification would go out shortly, followed by a 90-day period for customers to select an option. BioLife also expects to “burn through the remaining bag inventory,” and de Greef said the company expects margin improvement to begin flowing through in “either Q4 or Q1 of 2027, depending on how quickly we burn through the existing bag inventory.” Wichterman said GAAP operating expenses were $17.5 million, up from $15.3 million in the prior-year quarter. He attributed the increase to a $1.2 million rise in R&D expense, primarily related to the PanTHERA acquisition in April 2025 and the opening of a Center of Excellence. He also cited a $0.9 million increase in stock-based compensation acceleration related to severance, partially offset by a $0.8 million reduction in acquisition costs. Adjusted operating expenses were $16.8 million, compared with $13.8 million in Q1 2025. GAAP operating income was $27,000, compared with an operating loss of $0.5 million a year earlier. Adjusted operating income was $1.0 million versus $1.2 million in the prior-year period. BioLife posted GAAP net income of $1.2 million, or $0.02 per share, compared with $0.3 million, or $0.01 per share, in Q1 2025. Wichterman said the improvement was primarily driven by higher revenues. Asked about the higher R&D spend, de Greef said it was tied to the Center of Excellence, which added “four or five scientists… all PhDs,” and to accelerating internal projects. He highlighted development of an “RCC,” described as a rigid container intended to address the bag issue by transporting product “in a rigid container that can be used in a closed system,” and investment in “the consumable line associated with the CT-5.” Wichterman said cash and marketable securities totaled $111.5 million as of March 31, 2026, down from $120.2 million at year-end 2025. He attributed cash usage primarily to $5.6 million in tax obligations for share withholdings, $2.5 million in debt principal payments, and $6.9 million of unfavorable working capital, including a $5.1 million increase in accounts receivable due to timing. The company’s Silicon Valley Bank debt balance of $2.5 million is considered short-term, Wichterman said, with a final payment due in June 2026, including a $1.2 million balloon payment at maturity. Management reiterated full-year 2026 guidance of $112.5 million to $115.0 million in revenue, representing 17% to 20% growth. Wichterman said the outlook is primarily driven by expected demand from BPM customers with commercially approved therapies and increased demand for other tools. The company expects full-year GAAP and adjusted gross margin in the “mid-60s,” with benefits from pricing partially offset by mix and bag yield impacts. De Greef said BioLife anticipates “generating full-year GAAP net income for the first time in many years,” and Wichterman reiterated expectations for full-year positive GAAP net income and adjusted EBITDA margin expansion in 2026 compared to 2025. In response to a question from KeyBank analyst Paul Knight, Wichterman clarified the goal is profitability “for the full year, per quarter.” On broadening beyond BPM, de Greef said CellSeal vials and the company’s hPL product lines are used in four approved therapies and more than 35 clinical programs, supporting cross-selling efforts. He said adoption cycles at large organizations can be lengthy due to validation requirements, but suggested that integrating additional BioLife products into a therapy could raise revenue per dose “by 2 to 3 times relative to BPM alone.” In the Q&A, de Greef said BioLife remains on track for a Q4 launch of the PanTHERA product, adding the company has identified the value proposition and “the final molecule” it will pursue. He also commented on CryoCase, noting the product received a Best in Show award at INTERPHEX and that BioLife has “well over three dozen” validations underway, with hopes for traction in the second half of the year. On industry conditions, de Greef told TD Cowen analyst Brendan Smith that biotech funding dynamics generally do not meaningfully impact BioLife, because the company’s growth is largely driven by “well-capitalized firms,” with funding changes mainly affecting early-stage customers that buy small amounts through distributors. Looking ahead, de Greef said BioLife will continue focusing on operational execution, supporting core BPM customers, expanding adoption across its portfolio, and efficiently managing operations. He also said the company is evaluating strategic initiatives—including selective acquisitions, minority investments, and partnerships—enabled by what he described as balance sheet flexibility. BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife's product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells. The company's flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies. The article "BioLife Solutions Q1 Earnings Call Highlights" was originally published by MarketBeat. View MarketBeat's top stocks for May 2026.

Total revenue of $27.5 million, up 25% over Q1 2025 GAAP gross margin and non-GAAP adjusted gross margin of 64% GAAP net income of $1.2 million and non-GAAP adjusted EBITDA of $6.2 million or 22% of revenue Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash., May 7, 2026 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene therapy ("CGT") market, announces financial results for the three months ended March 31, 2026. "We delivered a solid start to 2026, with first quarter revenue up 25% year-over-year and adjusted EBITDA of $6.2 million," said Roderick de Greef, Chairman and Chief Executive Officer of BioLife Solutions. "Healthy demand for our biopreservation media and growth across our broader product portfolio reinforces our market leading position, while high-margin, recurring revenue drives a strong financial profile. Our products are embedded across a significant portion of commercial therapies and clinical pipelines, and we are seeing continued momentum across the CGT landscape including expansion into larger indications, encouraging data readouts, renewed funding activity and strategic M&A. This positions us well for the next phase of growth in this market and we remain confident in our full year outlook." First Quarter 2026 Business Highlights Our biopreservation media is utilized in approximately 250 ongoing commercially sponsored clinical trials in the U.S., representing a more than 70% market share. This includes over 30 Phase III trials, or nearly 80% of these late-stage trials. Our CellSeal vials and hPL products are used in over 35 clinical trials. Our biopreservation media is embedded in 17 unique commercial CGTs as of March 31, 2026, with expectations that approvals for 9 additional products, geographic expansions, earlier lines of treatment, or new indications will occur over the next 12 months. Our CellSeal cryogenic vials and hPL products are embedded in four approved therapies. First Quarter 2026 Financial Results BioLife is presenting various financial metrics under U.S. generally accepted accounting principles (GAAP) and as adjusted (non-GAAP). In addition, BioLife completed the divestiture of evo in 2025, and is presenting its financial condition and operating results as discontinued operations for all periods presented within the Unaudited Condensed Consolidated Balance Sheets and Unaudited Condensed Consolidated Statements of Operations. The Unaudited Condensed Consolidated Statements of Comprehensive Income (Loss) and Unaudited Condensed Consolidated Statements of Cash Flows are presented on a consolidated basis for both continuing operations and discontinued operations. All amounts, percentages, and disclosures for all periods presented reflect only the continuing operations of the Company unless otherwise noted. REVENUE Total revenue for the first quarter of 2026 was $27.5 million, an increase of $5.4 million, or 25%, from $22.1 million for the first quarter of 2025 and up $2.7 million, or 11%, from the fourth quarter of 2025. GROSS MARGIN Gross margin (GAAP) for the first quarter of 2026 was 64% compared with 67% for the first quarter of 2025. Adjusted gross margin (non-GAAP) for the first quarter of 2026 was 64% compared with 68% for the first quarter of 2025. OPERATING INCOME / (LOSS) Operating income (GAAP) for the first quarter of 2026 was $27 thousand compared with an operating loss of $0.5 million for the first quarter of 2025. Adjusted operating income (non-GAAP) for the first quarter of 2026 was $1.0 million compared with $1.2 million for the first quarter of 2025. NET INCOME Net income (GAAP) for the first quarter of 2026 was $1.2 million compared with $0.3 million for the first quarter of 2025. Adjusted net income (non-GAAP) for the first quarter of 2026 was $2.1 million compared with $2.0 million for the first quarter of 2025. NET INCOME PER SHARE Net income per share (GAAP) for the first quarter of 2026 was $0.02 compared with $0.01 for the first quarter of 2025. ADJUSTED EBITDA Adjusted EBITDA, a non-GAAP measure, for the first quarter of 2026 was $6.2 million, or 22% of revenue, compared with $5.4 million, or 24% of revenue, for the first quarter of 2025. CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES Cash, cash equivalents, and marketable securities as of March 31, 2026, were $111.5 million. 2026 Financial Guidance BioLife is reiterating its 2026 financial guidance as follows: Revenue of $112.5 million to $115.0 million, representing growth of 17% to 20% compared with 2025 revenue from continuing operations; Gross margin (GAAP) and adjusted gross margin (non-GAAP) in the mid-60% range; Net income (GAAP) for the full year; and Continued expansion of adjusted EBITDA margin (non-GAAP). Conference Call & Webcast Management will discuss the Company's financial results, provide a business update and answer questions during a conference call and live webcast today at 4:30 p.m. ET (1:30 p.m. PT). To access the webcast, log onto the Investor Relations page of the BioLife Solutions website at https://www.biolifesolutions.com/earnings. In addition, the conference call will be accessible by dialing toll-free 1-833-630-0431 or 1-412-317-1808 for international callers. A webcast replay will be available approximately two hours after the call ends and will be archived on https://www.biolifesolutions.com for 90 days. About BioLife Solutions BioLife is a leading developer and supplier of cell processing tools and services for the CGT market. Our expertise facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during the collection, development, manufacturing and distribution. For more information, please visit www.biolifesolutions.com, and follow BioLife on LinkedIn and X. Cautions Regarding Forward Looking Statements Certain statements contained in this press release are not historical facts and may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "plans," "expects," "believes," "anticipates," "designed," "may," "estimate," "guidance," and similar words are intended to identify forward-looking statements. Forward-looking statements are based on our current expectations and beliefs, and involve a number of risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those stated or implied by the forward-looking statements. A description of certain of these risks, uncertainties and other matters can be found in filings we make with the U.S. Securities and Exchange Commission, all of which are available at www.sec.gov. Because forward-looking statements involve risks and uncertainties, actual results and events may differ materially from results and events currently expected by us. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We undertake no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in its expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Non-GAAP Measures of Financial Performance To supplement our financial statements, which are presented on the basis of U.S. generally accepted accounting principles (GAAP), the following non-GAAP measures of financial performance are included on a consolidated basis in this release: adjusted gross margin, adjusted operating expenses, adjusted operating income/(loss), adjusted net income/(loss), earnings before interest, taxes, depreciation and amortization (EBITDA), and adjusted EBITDA. A reconciliation of GAAP to adjusted non-GAAP financial measures is included as an attachment to this press release. We believe these non-GAAP financial measures are useful to investors in assessing our operating performance. We use these financial measures internally to evaluate our operating performance and for planning and forecasting of future periods. We also believe it is in the best interests of investors to provide this non-GAAP information. While we believe these non-GAAP financial measures provide useful supplemental information to investors, there are limitations associated with the use of these non-GAAP financial measures. These non-GAAP financial measures may not be reported by competitors, and they may not be directly comparable to similarly titled measures of other companies due to differences in calculation methodologies. The non-GAAP financial measures are not an alternative to GAAP information and are not meant to be considered in isolation or as a substitute for comparable GAAP financial measures. They should be used only as a supplement to GAAP information and should be considered only in conjunction with our consolidated financial statements prepared in accordance with GAAP. Media & Investor Relations At the Company Troy Wichterman Chief Financial Officer (425) 402-1400 [email protected] Investors Alliance Advisors IR Jody Cain (310) 691-7100 [email protected] View original content to download multimedia:https://www.prnewswire.com/news-releases/biolife-solutions-reports-first-quarter-2026-financial-results-302766138.html

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Performance was driven by a 25% increase in revenue, primarily from the biopreservation media (BPM) franchise, which now represents over 85% of total revenue. Growth is increasingly anchored by customers with approved commercial therapies, who now account for roughly half of BPM revenue and are less sensitive to broader biotech funding cycles. The company maintains a dominant market position, with products embedded in 17 approved therapies and over 70% market share in commercially sponsored CGT clinical trials. Management is executing a cross-selling strategy to integrate CellSeal Vials and hPL products into existing BPM workflows, which can increase revenue per dose by 2 to 3x. Operational leverage is improving through a simplified business model focused on high-margin recurring revenue, despite temporary headwinds from manufacturing yields. Strategic positioning is benefiting from the CGT market's expansion into larger autoimmune and solid tumor indications, alongside a recovery in sector funding. Reiterated full-year 2026 revenue guidance of $112.5 million to $115 million, assuming 17% to 20% growth based on current customer demand forecasts. Management expects to achieve positive full-year GAAP net income for the first time in several years, supported by continued operating and adjusted EBITDA margin expansion. The PanTHERA product launch remains on track for Q4 2026, with the value proposition and final molecule selection already identified. Visibility into the next 12 months includes 9 unique anticipated approvals, indication expansions, or geographic rollouts for therapies utilizing BioLife products. Capital allocation will prioritize high-return organic growth and disciplined strategic M&A that broadens the platform's participation in the CGT ecosystem. Gross margins were impacted by a product mix shift toward bags and specific manufacturing yield issues, which management characterizes as transitory. A 90-day customer notification period is expected to begin shortly to transition to alternative bag options, with margin recovery expected to flow through in Q4 2026 or Q1 2027. R&D expenses increased due to the opening of the Center of Excellence and the acquisition of PanTHERA, reflecting a shift toward deeper internal scientific research. The company is developing a 'Rigid Cell Container' (RCC) as a long-term solution to current bag yield issues, designed for use in closed manufacturing systems. One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here. Management is providing customers with several bag alternatives and will issue formal notifications shortly, followed by a 90-day selection period. Enhanced margins are expected once existing bag inventory is exhausted, likely in late 2026 or early 2027. Once yield issues are rectified, bag margins are expected to align more closely with bottle margins. Management noted that funding volatility primarily affects early-stage customers who contribute minimally to total revenue. The bulk of revenue growth is driven by well-capitalized firms and late-stage programs that have stabilized following a recovery in sector financing. The funding environment is no longer viewed as a significant headwind for the company's commercial trajectory. There are currently over 3 dozen active validations for CryoCase, though adoption cycles are long due to 'decision by committee' at large pharmaceutical firms. Management anticipates gaining commercial traction and potentially announcing recognizable customers in the second half of the year. Internal data shows market share shifting further in BioLife's favor as clinical trials progress toward commercialization. Management believes it is increasingly difficult for companies to justify non-standardized 'homebrew' solutions to the FDA for commercial-scale therapies.

Image source: The Motley Fool. Thursday, May 7, 2026 at 4:30 p.m. ET Chief Financial Officer — Troy Wichterman President and Chief Executive Officer — Roderick de Greef Roderick de Greef: Thanks, Troy. Good afternoon, everyone, and thank you for joining us for BioLife's First Quarter 2026 Conference Call. We're off to a solid start to 2026 with first quarter revenue growth of 25% and adjusted EBITDA up approximately 15% versus the prior year. Performance in the quarter was driven by continued strength across our broader product portfolio, led by our biopreservation media or BPM franchise. We entered 2026 with a simplified business and heightened focus on high-margin recurring revenue, and our results this quarter demonstrate the operating leverage in our model as a result. At the same time, we're seeing continued momentum across the CGT landscape, driven by expansion into larger indications, encouraging data readouts, strategic M&A and an improving funding environment, all of which we believe will support long-term growth across our end markets and underpins sustained value creation for BioLife shareholders. Turning to the quarter's results. Total revenue reached $27.5 million, increasing 25% year-over-year and adjusted EBITDA of $6.2 million or 22% of revenue, up roughly 15% from the prior year. BPM remained the primary driver of revenue growth with our other cell processing tools also contributing to overall growth. BPM represents over 85% of total revenue and continues to benefit from broad adoption across both commercial therapies and clinical pipelines where we maintain a dominant market share. Our top 20 BPM customers represented approximately 80% of BPM revenue and demand forecast from these accounts provide good visibility into our business. Channel mix remained consistent with over 60% of BPM revenue generated through direct sales with the balance through third-party distributors. Roughly half of BPM revenue was generated from customers with approved commercial therapies, and this remains a key driver of growth and durability in our model. We highlight these metrics because they reflect the ongoing shift in our business toward later-stage programs and commercial products, which are more stable, less sensitive to funding dynamics and growing faster than the broader CGT market. Several of the therapies we support are already at or tracking toward blockbuster status with annual revenues exceeding $1 billion. As these therapies scale and expand into new geographies and additional potentially larger indications, we believe BioLife is well positioned to benefit from higher patient volumes and the recurring nature of these revenue streams. Gross margin and adjusted EBITDA as a percent of revenue declined year-over-year due to the previously discussed bag yield dynamics. This remains a key operational priority, and we are making steady progress in close collaboration with our key customers to address it and are confident that this is temporary in nature. Stepping back, our market position continues to strengthen. At the end of the quarter, our BPM products were embedded in 17 approved therapies with visibility into an additional 9 unique approvals, expanded indications and geographic expansions over the next 12 months. Across the broader pipeline, we estimate our solutions are utilized in more than 250 commercially sponsored CGT clinical trials in the U.S., exceeding a 70% market share with an even higher share in later-stage Phase III programs. Independent third-party analysis of U.S. commercially sponsored trials where our biopreservation media is not used, no other commercial alternatives were identified, suggesting that these trials are relying on internal homebrew formulations. Given our leading share among late-stage programs, we expect this pipeline will convert into future commercial revenue as therapies advance through the approval process, reinforcing our position as a critical spectrum component of the cell therapy workflow. Building on this foundation, our team is focused on expanding BioLife's role within the CGT workflow beyond biopreservation media. Our CellSeal Vials and hPL product lines are already utilized in 4 approved therapies and over 35 clinical programs, and that number continues to grow. This expanding footprint is supporting our cross-selling efforts with existing BPM-only customers evaluating additional components of our portfolio. Given the size of these organizations and the rigor of their validation processes, adoption cycles tend to be longer, reflecting a higher bar for change while reinforcing the stickiness of these relationships. That said, we're seeing encouraging early traction and each additional BioLife product that's integrated into a therapy has the potential to increase our revenue per dose by 2 to 3x relative to BPM alone. While still early, this represents a meaningful opportunity to enhance both growth and the overall financial profile of the business. From a capital allocation standpoint, we remain focused on the highest return opportunities to support long-term growth, both organically and through disciplined strategic initiatives. Alongside our cross-selling efforts, we are regularly evaluating adjacent areas that build on our core scientific and commercial strengths. This includes selective acquisitions, minority investments and strategic partnerships that broaden our platform and increase our participation across the CGT ecosystem. This is enabled by our balance sheet, which gives us the flexibility to pursue attractive opportunities with discipline while maintaining a high bar for financial profile and strategic fit. Turning to our 2026 outlook. We are affirming the guidance we introduced on our last call. We expect revenue of $112.5 million to $115 million for the year, representing growth of 17% to 20%. As in prior years, our guidance reflects the visibility we have today based on demand forecast from our key customers. We also expect continued operating and adjusted EBITDA margin expansion and anticipate generating full year GAAP net income for the first time in many years. Before handing it over, I'll briefly highlight a few favorable developments we're seeing across the cell therapy landscape. Field is diversifying beyond traditional oncology applications with increasing activity in large autoimmune indications. We're also seeing encouraging data emerging in allogeneic cell therapies that have the potential to unlock multibillion-dollar market opportunities as well as renewed interest in established autologous approaches such as CAR-T and TILs, expanding the market from its base in liquid tumors into solid tumor indications. At the same time, we're seeing meaningful strategic activity, including the recent nearly $8 billion acquisition of Arcellx by Gilead as well as continued investment in next-generation manufacturing capacity and automation to support scale. As these therapies evolve and care settings shift, whether into outpatient and community settings or toward off-the-shelf approaches, this is expected to support sustained demand for robust, high-quality and trusted cell processing tools, biopreservation media and packaging solutions, areas where BioLife is well positioned. Taken together, these dynamics reinforce our confidence in the long-term trajectory of the field and the attractiveness of the CGT end market. BioLife has exposure across these areas and is uniquely positioned to benefit as these trends translate into durable demand. With that, I'll hand the call over to Troy to provide an overview of our first quarter financial results. Troy? Troy Wichterman: Thank you, Rod. We reported Q1 revenue of $27.5 million, representing an increase of 25% year-over-year. The year-over-year increase was primarily related to increased sales of our biopreservation media products, driven by strong demand from customers with commercially approved therapies as well as strong revenue growth from the balance of our product portfolio. GAAP gross margin for Q1 2026 was 64% compared with 67% in Q1 2025. Adjusted gross margin for the first quarter was 64% compared with 68% in the prior year. The decrease in adjusted gross margin percentage compared with the prior year can primarily be attributed to a product mix shift towards bags, which carry lower gross margins than bottles as well as a previously discussed impact from manufacturing yields. We view the yield impact as transitory and a key operational priority throughout 2026. And as it is resolved, we expect a corresponding expansion in gross margin. GAAP operating expenses for Q1 2026 were $17.5 million versus $15.3 million in Q1 2025. The increase compared to the prior year can be attributed to a $1.2 million increase in R&D, primarily related to our PanTHERA acquisition in April 2025 and the opening of our Center of Excellence. In addition, we had a $0.9 million expense increase in stock-based comp acceleration related to severance, partially offset by a reduction of $0.8 million in acquisition costs. Adjusted operating expenses for Q1 2026 totaled $16.8 million compared with $13.8 million in the prior year. GAAP operating income for Q1 2026 was $27,000 versus an operating loss of $0.5 million in the prior year. The improvement was primarily due to increased revenue compared to the prior year and lower acquisition costs, partially offset by higher stock comp related to severance. Our adjusted operating income for the first quarter of 2026 was $1 million compared with $1.2 million in Q1 2025. Our GAAP net income was $1.2 million or $0.02 per share in Q1 compared to $0.3 million or $0.01 per share in the prior year. The increase in net income was primarily due to increased revenues compared to the prior year. Adjusted EBITDA for the first quarter of 2026 was $6.2 million or 22% of revenue compared with $5.4 million or 24% of revenue in the prior year. The primary driver of the change as a percentage of revenue in the current quarter was due to the impact of bag yields on our gross margin percentage as discussed earlier. Turning to our balance sheet. Our cash and marketable securities balance reported as of March 31, 2026, was $111.5 million compared with $120.2 million as of December 31, 2025. Taking into consideration our adjusted EBITDA of $6.2 million in Q1, cash usage was primarily driven by tax obligations for share withholdings vested in Q1 of $5.6 million, debt principal payments of $2.5 million and unfavorable working capital of $6.9 million, which includes an increase in AR of $5.1 million, primarily related to timing. The entirety of our $2.5 million SVB debt balance is considered short term. Our final payment on the SVB debt balance is due in June 2026. We will pay a $1.2 million loan maturity balloon payment due at the time of maturity. Turning to our 2026 financial guidance. We are reiterating our 2026 guidance disclosed during our fourth quarter earnings call. Total revenue is expected to be $112.5 million to $115 million, reflecting overall growth of 17% to 20%. The increase is primarily due to expected demand from our BPM customers with commercially approved therapies as well as increased demand for our other tools. We expect GAAP and adjusted gross margin for the full year to be in the mid-60s. We expect gross margins to benefit from favorable pricing, partially offset by product mix and the previously discussed impact from bag yields. We expect to achieve full year positive GAAP net income and expansion of adjusted EBITDA margin in 2026 compared to 2025. Finally, in terms of our share count, as of April 30, we had 48.9 million shares issued and outstanding and 50.3 million shares on a fully diluted basis. Now I'll turn the call back to the operator to open up for questions. Operator: [Operator Instructions] And our first question comes from Matt Stanton from Jefferies. Matthew Stanton: Maybe on the topic of the bags, could you just clarify, are you saying that the bags have lower margins than bottles, all else equal and that there's also the scrap issue tied to the bag, so kind of two issues on the bag in terms of mix? And then I would love to just get an update on the scrap side of the bag. I think before you talked about kind of a 90-day notice period. Maybe just help us in terms of getting that back to normal as we think about kind of the 22% adjusted EBITDA margins in 1Q and the walk up the rest of the year to kind of get to that year-over-year expansion that you reiterated again today. Roderick de Greef: Yes, Matt, let me take the second part of your question, and I'll have Troy deal with the first part. So with respect to where we are with our customers in order to solve this problem, we have been working with them over the last 60 days to provide them with several different alternatives to the existing bags, which are causing the problems. So we are at a point now where that customer notification will be going out shortly. There's a 90-day period for them to select effectively which option they'd like to utilize. And then we have to burn through the remaining bag inventory that we have. So we're on track for the same sort of timing as we had laid out in the last phone call we had. And we would expect to be able to see some flow-through of enhanced margin either Q4 or Q1 of '27, depending on how quickly we burn through the existing bag inventory. I'll let Troy answer the rest. Troy Wichterman: Yes. And Matt, on your question on bags versus bottles on gross margin. So as a percentage of revenue, bags do have a lower gross margin than bottles by quite a bit at this point in time because of that yield issue we've been talking about. Matthew Stanton: Okay. And then so once the yield issue is rectified, are the margins closer to the same as previous is that right? Troy Wichterman: Closer, correct. Matthew Stanton: Okay. Okay. And then maybe, Rod, you talked about a little bit just outside of biopreservation media, you talked a little bit about cross-selling there. I would love just some more color on the new product front. Obviously, you have the Cryo case. I think you've talked about maybe some other things coming out of the pipeline. You have PanTHERA here, would love kind of an update on that. Just anything as we think about the back half of '26 and '27 on the new product front and other things coming out besides biopreservation media. Roderick de Greef: Sure. You bet. With respect to the PanTHERA product, we're still on track for a Q4 launch of that. We've identified what the value proposition will be in addition to identifying the final molecule that we'll be going with. So that looks good. With respect to cross-selling the other products, that is a longer-term effort. It continues to move forward with respect to increased number of validations, et cetera. And I think that at the end of the day, when I look at the revenue growth, albeit from a smaller base, those other tools are growing at a faster rate actually than the biopreservation media is. So we're pleased with the momentum. Obviously, we'd like things to go faster, but there's a certain amount of inertia with respect to the validation process within these large companies. Operator: The next question comes from Brendan Smith from TD Cowen. Brendan Smith: Congrats on the quarter. Maybe just a quick one from us on a bit more sector level. I guess as you kind of look at state of biotech funding and kind of the broader strength you're seeing, are you potentially expecting any inflection orders over the coming months? I guess, just given that we're now kind of approaching almost 6 months of pretty solid funding recovery there. I guess, really, how big of a driver is that for BioLife realistically? And is this something that could jump up in Q3 or Q4? Or just kind of your view on the funnel looking like a more gradual ramp? Just kind of trying to understand cadence for guidance. Roderick de Greef: Yes. Thanks, Brendan. I think that as we've talked in the past, the biotech funding does not really impact us. To the extent that it does, it impacts us at very early-stage customers. There's a few exceptions to that. But in general, it affects earlier-stage customers that buy a very small amount of product through distributors from us, right? So the overall impact is not that meaningful. The bulk of the revenue, certainly the revenue growth is coming from well-capitalized firms. And when I look at the Phase III customers that we have that should be gaining approval over the next sort of 12 to 24 months, those are, by and large, also well capitalized. On top of that, though, to the extent there is an impact, I read the other day where overall biotech financings for '25 were about $11.1 billion. So it seems to me that, that issue has stabilized and now should not be a headwind at any level for us going forward. Operator: The next question comes from Paul Knight from KeyBanc. Paul Knight: Rod, we were at the BioLife booth at INTERPHEX, the CryoCase won one of the Best In Show awards. How is that going commercially? Roderick de Greef: Yes. We were pleased to receive the award for sure, Paul. I think it's good recognition that it truly was sort of a unique product that we put out. So again, we have well over 3 dozen validations going on, and I think that there's definite interest. But again, whenever you're dealing with something that changes in the manufacturing process, particularly of a final drug product, but even in late stage, it's a decision by committee, right? A lot of people are involved, and it takes a lot of time. But we're seeing some bright spots and are looking forward to being able to see some traction certainly towards the second half of the year, hopefully, with the type of announcement of a customer that people would recognize. Paul Knight: And then the other question, Rod, you mentioned earlier, autologous has kind of been the core of the market. But where are we with allogeneic cell therapy based on what customers are telling you? Roderick de Greef: Yes. I think we're still a couple of years out, but Allogene has published some decent data. I think they did a raise. So from a financial perspective, they're in a much more solid position. And I think there, although the overall BPM volumes per patient might be a little bit lower, the opportunity to address much larger patient populations is, in our estimation, going to far outweigh the reduced amount of volume per patient. But again, I think it's a good 2-plus years away from really having a revenue impact on BioLife. Paul Knight: And then lastly, you mentioned GAAP net income. Is that like targeting 4Q, Rod, or Troy? Roderick de Greef: No, it's for the full year per quarter, Paul. Operator: The next question comes from Mac Etoch from Stephens. Steven Etoch: Maybe following up on Paul's question. I think the share of homebrew has been pretty stable over the last couple of years, particularly in late-stage trials. As you think about cell and gene therapy expanding into these larger indications and the FDA focusing on more standardized platforms, do you see an opportunity to kind of capture more of that share moving forward? Roderick de Greef: Yes, I think so. As we're taking a cut of this data, Matt, on every 6-month basis. We go back and review the results of all the clinical trial work that has been done and refresh it. And the numbers are actually going up in our favor. So I think that at the end of the day, it's going to be very few folks who use a homebrew with a commercial product. As we've mentioned, we're in 900-plus trials worldwide, but the ones that really matter are the 250-plus that we're in that are commercially sponsored that are looking to achieve a commercial therapy. And I think that it's going to be increasingly difficult to justify whether it's from a cost perspective, a manufacturing process perspective, a logistics perspective, the FDA to use something other than the gold standard. Operator: The next question comes from Matt Hewitt from Craig-Hallum. Tollef Kohrman: This is Tollef Kohrman on for Matt Hewitt. Is there anything specific you want to call out on that increase in R&D expense? Roderick de Greef: Yes. I think it is directly related to bringing on the Center of Excellence, which provides us with the ability to do some serious scientific work. We have 4 or 5 scientists working at the center, all PhDs. We've never had that before in terms of a team of scientists that can actually do the R part in addition to the D part of R&D. So we're pretty pleased with that. So there's a cost associated with that as well as the cost of increasing the accelerating projects that we have internally, including the RCC, which will ultimately be the answer to the bag issue that we have. So that's a rigid container designed to carry our product from our factory to our customers in a rigid container that can be used in a closed system. So that's a product that we're definitely making an investment in as well as the consumable line associated with the CT-5. So that's where the money is going. It's really internal product development. Operator: The next question comes from Thomas Flaten from Lake Street Capital Markets. Thomas Flaten: Rod, you mentioned in your prepared comments that commercial BPM customers were about half the revenue. And I think on the last call, you said you could get that maybe up to 55%. Any update on that outlook? Or do you think 55% is still realistic? Or do you think you can push it beyond that? Roderick de Greef: I think in the near term, that's about the right number. The rate of growth of that group of customers versus, say, distribution or noncommercial is so significantly different that it's going to be a higher number in the outer years. But in this year, I think a target of 55% is pretty much where we're going to settle out. Operator: And our next question comes from Yi Chen from H.C. Wainwright. Katherine Degen: This is Katie on for Yi. Thinking about some of the deals you announced on prior calls with Pluristyx and Qkine with those two coming together and that announcement on May 1, does that integration kind of give you any meaningful wins for biopreservation media demand? Are you kind of expecting any pull-through from that deal? How are you kind of thinking about that? Roderick de Greef: are you speaking about the Qkine deal? Katherine Degen: Yes. Roderick de Greef: Yes. I think where the pull-through with our products comes into play is combining our CellSeal product line as a primary container for Qkine cytokine line. That's where we're going to see some incremental revenue from our products. The other way we'll generate revenue is obviously through the sale of their cytokines to our customer base. Katherine Degen: Yes. I guess my question is, are you expecting any synergy now that Pluristyx and Qkine have an agreement together? Roderick de Greef: You mean the Pluristyx and Qkine agreement? Katherine Degen: Yes, right. Roderick de Greef: No, no. I think -- yes, that's specific to Qkine providing some products that have -- that are relevant to their Organoid kit. So that really is outside of anything to do with BioLife per se. Katherine Degen: Okay. So you don't think they'll pull through any customer base from that? Roderick de Greef: Not that will directly impact our revenue in any way, no. Operator: This concludes our question-and-answer session. I would like to turn the conference back over to Rod de Greef for any closing remarks. Roderick de Greef: Thank you, Jason. In closing, 2026 is off to a strong start with solid top line growth. We remain focused on operational execution, including supporting our core BPM customers, expanding adoption across our broader portfolio and managing operations efficiently across our organization. We believe our position as a leading supplier of bioproduction products, together with exposure across the attractive and growing CGT end market leaves us well positioned for durable growth and long-term value creation. Thank you for your time today, and I look forward to seeing some of you at upcoming investor conferences. Operator: The conference has now concluded. Thank you for attending today's presentation. You may now disconnect. Before you buy stock in BioLife Solutions, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and BioLife Solutions wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $475,926!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,296,608!* Now, it’s worth noting Stock Advisor’s total average return is 981% — a market-crushing outperformance compared to 205% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors. See the 10 stocks » *Stock Advisor returns as of May 8, 2026. This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. BioLife (BLFS) Q1 2026 Earnings Transcript was originally published by The Motley Fool

BioLife Solutions, Inc. (BLFS) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to earnings of $0.04 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +700.00%. A quarter ago, it was expected that this company would post a loss of $0.02 per share when it actually produced earnings of $0.04, delivering a surprise of +300%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. BioLife Solutions, which belongs to the Zacks Medical - Products industry, posted revenues of $27.5 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 7.78%. This compares to year-ago revenues of $23.94 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. BioLife Solutions shares have lost about 10.1% since the beginning of the year versus the S&P 500's gain of 7.6%. While BioLife Solutions has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for BioLife Solutions was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #1 (Strong Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.02 on $27.28 million in revenues for the coming quarter and $0.09 on $113.33 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the bottom 38% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Jushi Holdings Inc. (JUSHF), another stock in the same industry, has yet to report results for the quarter ended March 2026. The results are expected to be released on May 12. This company is expected to post quarterly loss of $0.06 per share in its upcoming report, which represents a year-over-year change of +33.3%. The consensus EPS estimate for the quarter has been revised 16.7% higher over the last 30 days to the current level. Jushi Holdings Inc.'s revenues are expected to be $66.4 million, up 4% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report BioLife Solutions, Inc. (BLFS) : Free Stock Analysis Report Jushi Holdings Inc. (JUSHF) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Image source: The Motley Fool. Thursday, Feb. 26, 2026 at 4:30 p.m. ET Chief Financial Officer — Troy Wichterman Interim Chief Executive Officer — Roderick de Greef Need a quote from a Motley Fool analyst? Email [email protected] Roderick de Greef: Thanks, Troy. Good afternoon, and thank you for joining us for BioLife Solutions, Inc.'s fourth quarter and full year 2025 conference call. 2025 was another strong year for BioLife Solutions, Inc., delivering double-digit revenue growth, operating margin expansion, and improved profitability. Throughout the year, we executed consistently against our key strategic priorities, advanced our efforts to reposition the portfolio, and strengthened the foundation to scale the business for years ahead. We exit the year simpler, more focused, and structurally stronger. With the divestiture of our EVO product line behind us, we enter 2026 with a strong balance sheet and a fully optimized portfolio that plays to our strengths and positions BioLife Solutions, Inc. to drive sustainable, profitable growth and shareholder value. Compared to 2024, our 2025 results from continuing operations demonstrate our increasingly attractive financial profile, which is driven by the culmination of our multiyear strategic transformation, a streamlined portfolio centered on market-leading consumables, and sustained growth from our commercial CGT customers, which reinforces our positioning to benefit from the continued growth and maturity of our end market. On the top line, total revenue grew 29% to $96 million, landing at the high end of our guidance, which was raised twice in the second half of the year. While gross margin experienced a decline year over year, primarily reflecting product mix and lower bag yields in the second half, operating leverage more than offset this impact and contributed to an increase in adjusted EBITDA of $25 million, or 26% of revenue, up from $13 million, or 18% in 2024. In the fourth quarter, total revenue reached $24.8 million, increasing 20% year over year, driven primarily by continued strength in our biopreservation media, or BPM, franchise with broad-based growth across our entire cell processing tools portfolio. Turning to Q4 revenue composition, our BPM product line accounted for approximately 85% of total revenue, with our top 20 BPM customers continuing to account for roughly 80% of BPM revenue. This concentration provides enhanced visibility into demand across the core part of our business. These metrics remain consistent with prior quarters and reinforce the stability of our recurring revenue base. Staying with our BPM products, direct customers continue to represent the majority of our mix versus distribution, and commercial BPM customers accounted for nearly 50% of revenue, up from the low-40s range in 2024. Both of these metrics reflect the ongoing shift toward later-stage and approved therapies that support both near-term and long-term growth. Stepping back from the quarter, our position within the broader CGT landscape remains strong. Our BPM products are embedded in 16 approved therapies and utilized in more than 250 relevant commercially sponsored CGT trials in the U.S., representing over 70% share. This includes more than 30 phase 3 trials in which our share is approaching 80%, underscoring BioLife Solutions, Inc.'s position as the partner of choice for later-stage clinical programs where success rates are higher and the path to commercial revenue is more clearly defined. Longer term, a key driver of CGT market growth remains the pace of FDA approvals, including unique therapy approvals, expanded indications, geographic expansion, and movement into earlier lines of treatment. While 2025 saw fewer approvals relative to 2024, we anticipate up to five unique therapy approvals over the next twelve months along with one new indication and at least one geographic expansion. We believe that the unique approval funnel is beginning to regain some momentum. This evolving regulatory backdrop supports our ability to capture additional value, especially within the late-stage programs we are already embedded in. Building on our BPM market leadership, we are working to expand our role within these clinical and commercial programs beyond biopreservation media. Our sales and marketing team is actively driving adoption of our broader cell processing tools across our marquee BPM customer base. As we have discussed previously, this cross-sell opportunity has the potential to increase our revenue per patient dose by two to three times relative to our BPM products alone, as customers incorporate additional components of our offering into their workflows. We have numerous product evaluations underway, including several with our largest commercial customers. While adoption cycles are lengthy, engagement remains strong and we expect to demonstrate some traction in 2026. Complementing our cross-sell strategy, we are also evaluating portfolio adjacencies that build on our scientific and commercial capabilities. In 2025, we assessed opportunities aligned with our product profile requirements that could broaden our product offering and bring additional value to our customers. One attractive strategic adjacency we identified is cytokines, which represent a natural complement to our emerging HPL product line. Earlier this month, we entered into a strategic distribution and product development agreement with UK-based Qkine Limited. The agreement provides us with exclusive distribution rights for certain cytokine products and nonexclusive rights for others within the CGT market. In addition, our product development teams will work together to package and store certain cytokine products in our CellSeal vial line. Our acquisition of Panthera and the investment in Pluristics last year, together with this new partnership, reflect our strategy to expand the platform through targeted M&A, minority investments, and strategic collaboration. These actions broaden our offering and increase our participation in the evolving cell therapy ecosystem. Turning to our outlook for 2026, we issued guidance this afternoon which included revenue between $112 million and $115 million, representing growth of 17% to 20%. As in prior years, our initial guidance reflects the visibility we have today based on the demand forecast from our key BPM customers. In addition, we see continued operating and adjusted EBITDA margin expansion and expect the company to generate full-year GAAP net income for the first time in many years. Before handing it over, I would like to comment on some recent developments in the cell therapy space, including encouraging clinical data in larger indications, continued advances in automation and manufacturing scalability, and renewed strategic investment by large pharma through multibillion-dollar acquisitions and next-generation facility buildouts, all of which reinforce our confidence in the long-term trajectory of the field and the attractiveness of the CGT market. BioLife Solutions, Inc. is well positioned as a market leader to benefit as these dynamics translate into durable demand over the long term. With that, I will hand the call over to Troy, who will provide an overview of our full Q4 and 2025 results and more details of 2026 guidance. Troy? Troy Wichterman: Thank you, Rod. Today, we will be reviewing current and prior period financials from continuing operations for Q4 and full year 2025 and providing 2026 financial guidance. Unless otherwise noted, all financial measures discussed reflect adjusted non-GAAP measures. Before we start with the financials, I am pleased to report we implemented our ERP manufacturing modules in February with no disruption to operations. This module allows for greater automated processes and controls in our manufacturing, quality, and accounting functions. This, in turn, provides a systematic foundation and automated processes to leverage into our planned growth. As shared in our press release today, we reported total Q4 revenue of $24.8 million, representing an increase of 20% over the prior year, and full-year revenue of $96.2 million, representing an increase of 29% over the prior year. The year-over-year increase in both periods primarily related to increased demand for biopreservation media from our customers with commercially approved therapies. For the full year 2025, we had growth across all product lines except our HPL media business, which was flat year over year due to certain import restrictions in China, which have since been abated. Adjusted gross margin for Q4 2025 was $15.8 million, or 64%, compared with $14.0 million, or 67%, in the prior year. Full-year adjusted gross margin was $63.2 million, or 66%, compared with $51.4 million, or 69%, in the prior year. The decrease in adjusted gross margin as a percentage of revenue in both periods was due to a continuing product mix shift toward bags, which carry lower gross margins than bottles, and we had lower-than-anticipated bag yields in the second half of the year. Improving bag yields is a clear operational priority as we enter 2026. Adjusted operating expenses for Q4 2025 totaled $14.7 million compared with $13.8 million in the prior year, and for the full year were $59.3 million compared to $52.9 million in the prior year. Adjusted operating income for Q4 2025 was $0.9 million compared with adjusted operating loss of $0.2 million in Q4 2024. Full-year adjusted operating income was $2.9 million compared to adjusted operating loss of $2.6 million in the prior year. Adjusted net income was $1.9 million in Q4 compared to adjusted net loss of $0.1 million in Q4 of the prior year. Adjusted net income for the full year was $6.3 million compared to adjusted net loss of $2.9 million in the prior year. The increase in adjusted operating income and adjusted net income was primarily driven by an increase in revenues year over year, in addition to a decrease in our sales tax accrual of $1.3 million. This was partially offset by increases in R&D expenses from increased headcount and investment in key projects. Adjusted EBITDA for Q4 2025 was $6.9 million, or 28% of revenue, compared with $3.7 million, or 18% of revenue, in Q4 of the prior year. Adjusted EBITDA for the full year was $25.0 million, or 26% of revenue, compared with $13.3 million, or 18% of revenue, in the prior year. Our adjusted EBITDA increased primarily due to higher revenue. In addition, we had a $1.3 million gain on a sales tax true-up recorded in Q4, which had approximately a 500 basis point impact on our adjusted EBITDA margin in Q4 and a 100 basis point impact for the full year. Turning to our balance sheet, our cash and marketable securities balance at 12/31/2025 was $120.2 million, compared with $98.4 million at 09/30/2025 and $105.4 million at 12/31/2024. Taking into consideration our adjusted EBITDA of $6.9 million, our increase in cash during Q4 2025 was primarily related to the $23.5 million in cash proceeds from the divestiture of SAVSU, partially offset by CapEx spend of $4.4 million, working capital usage of $2.2 million, and debt payments of $2.5 million. Our remaining SGD debt balance at 12/31/2025 was $5.0 million, all of which is short term. We expect to pay off the entirety of the loan by June 2026, in addition to a $1.2 million loan maturity balloon payment due at the time of maturity. Turning to 2026 financial guidance, total revenue is expected to be $112.5 million to $115.0 million, reflecting overall growth of 17% to 20%. The increase is primarily due to expected demand from our BPM customers with commercially approved therapies as well as increased demand for our other tools. We expect GAAP and adjusted gross margin for the full year to be in the mid-60s. We expect gross margins generally to be in line with 2025 due to favorable higher average selling prices, partially offset by product mix, primarily due to higher growth rates from our other cell processing tools. As Rod stated, we expect to achieve full-year positive GAAP net income and further expansion of adjusted EBITDA margins compared to 2025. The expected improvement in net income and adjusted EBITDA margins from 2025 is primarily driven by expected increased revenue, partially offset by expected increases in R&D and sales and marketing expenses to support our longer-term growth plans. Finally, in terms of our share count, as of 02/19/2026, we had 48.3 million shares issued and outstanding and 50.2 million shares on a fully diluted basis. Now, I will turn the call back to the operator to open up for questions. Thank you. Operator: We will now open for questions. The first question comes from Matthew Stanton with Jefferies. Please go ahead. Matthew Stanton: Maybe just to kick off for the guide, any more color you can provide in terms of assumptions between commercial and clinical? Rod, I think you said commercial went from low-40s to the mix to about 50. Can we see a similar magnitude of uptick in 2026 on the commercial side? And then just on the clinical side, are you starting to see some of the positive biotech funding data show up in activity levels or orders from customers? Just a little more flavor on what you are starting to see on the clinical side would be helpful as well. Thanks. And then just on the bag yield impact, is there any way to quantify what that was as a headwind in terms of margins in 2025? And then, Rod, I think you talked about it as a clear priority for 2026. Can you just talk a little bit more about timing and logistics in terms of resolving the bag yield headwind you saw in the back half of the year here? Thanks. Roderick de Greef: Sure. So we had a strong increase in our commercial customer revenue as a portion of total revenue. As we mentioned, it is about 20 points—actually, sorry, a little less than 10 points. But I think it is going to be not quite that much, and I would expect our commercial customers to be somewhere between 50%–55% in 2026. With respect to the second half of your question, we are not really seeing any significant uptick. And I think the reason for that is these customers are small, Matt. And so to the extent that they are either constrained or not constrained, the amount of product they buy from us is pretty small in their early stages. So we are really not seeing any major effect of that. As for bag yields, I think it is about a 2% or three-point headwind on gross margin in the second half of the year. I believe that we have found a solution to the issue. It is a solution that requires a 90-day customer notification. So we have that piece that is, by definition, built in from a timing perspective. And then in addition to that, we have to sell through the higher-cost inventory that we have, in terms of finished product that is in bags sitting in our warehouse, before we will start to see the impact of the higher-yield bags come through, which we expect would be right around Q4 of this year. Operator: The next question comes from Anna Snopkowski with KeyBanc Capital Markets. Please go ahead. Anna Snopkowski: Hi. This is Anna on for Paul. Thanks for taking my question and congrats on a great quarter. My first question is just around the CAR-T market. It seems like we are getting better patient access with the REMS removal. I was just wondering if you have seen this impact your top line at all or just customers' outlook at all? And then could you just remind us your exposure to CAR-Ts at this point? And then, just quickly following up on your outlook for 2026, how much would you say is rooted in commercial growth versus dependent on improving macro conditions in clinical trials? Or would you say most of your outlook is towards the commercial side? Thank you. Roderick de Greef: Yes. In terms of our commercial exposure, I would say it is at least over 80% with respect to CAR-Ts at this point, if not a little bit higher. It is really hard, Anna, to try to parse out the impact of REMS first. It just happened right within the last six months or so, and I think it is going to take a while for that to flow through to an increased number of patients being treated. So while we think it is an excellent move in the right direction—because I think patient access is probably the single largest constraint to the overall adoption—I have read where 20% of people who are eligible for CAR-T are actually receiving CAR-Ts. So I think patient access is a key factor in future growth, but it is hard to try to parse it out to the point of saying we have seen anything or not seen anything. And on 2026, I think it is fair to say that the primary driver for growth this year is going to be continued growth from the commercial customers that we have. Operator: The next question comes from Brendan Smith with TD Cowen. Please go ahead. Brendan Smith: Great. Thanks for taking the question, guys. I actually wanted to follow up on your commentary regarding the cross-selling there. Just a little bit more. Can you maybe expound a bit on really what ultimate success kind of looks like within that initiative? And sorry if I missed it, but can you just confirm if any contribution through that is included in some of your 2026 guidance assumptions? Or should we think of that more as upside? Roderick de Greef: Well, we have a base assumption around how much of the growth of our other tools—non-biopreservation media tools—that growth, how much of that is fundamentally related to therapies with respect to, for example, on the CellSeal vial side, versus new business that we are assuming to have come in. So we are pretty clear about that split, although we will not get that granular on this call. I think the ultimate measurement or metric at this time, at least for most of this year until we get a little bit more rigorous in our own data analysis, is the growth rate related to the non-BPM tools versus BPM. And we do expect, as a basket, that the non-BPM tools will grow at a faster percentage rate than BPM, in part because it is a smaller base that we are starting from. But as we put more focus on this and our systems get up to speed, we should be able to start speaking to the number of customers that are using one of our products, two of our products, three or more of our products. And that is definitely a goal internally to pull those metrics together and then figure out a way to report that externally. Operator: The next question comes from Steven Etoch with Stephens. Please go ahead. Steven Etoch: Hey, good afternoon and thank you for taking my questions. Maybe one on the partnership agreement you signed earlier this year. It is a pretty interesting deal, maybe a little outside of your normal deal structure, but what can you share with us just in terms of maybe the adoption potential of that product with your CellSeal vials and all that? And secondly, what could the margins look like for that type of business? Roderick de Greef: Yes. So I am not going to speak specifically to the margins, Mac, just from a competitive perspective. But we certainly have a margin profile that reflects the volume that we anticipate to move. With respect to the combination of their cytokines and our CellSeal vials, that is probably a six- to nine-month development project right there. So we would not expect to see much in the way of that revenue, in terms of pull-through on the CellSeal vial side of things, until the end of this year, early next. But this is a long-term strategic move for us. It is not about generating X amount of revenue in 2026, although we will drive some revenue. But really it is a longer-term market segment, product category that we want to be in, and feel we can win there, and that is why we are there. Steven Etoch: Appreciate that. And then maybe you touched on the bags being an issue in the second half of last year. But as it relates to CryoCase, do you see that as a potential opportunity to maybe reduce scrap and improve margins long term as CryoCase is adopted? Roderick de Greef: Yes. So it is important to keep in mind that the CryoCase, as it is configured today, is designed for the final product going from the developer’s factory to the patient. The rigid container—what we call the RCC—is designed and being designed to take 100 mL of our product from our factory to our customer, which is where we have the bag problem. Right? So currently, we are shipping most of our commercial product in bags from our facility to the developer’s facility, and then they drain that and they use it in their workflow. The idea would be to replace that bag on the front end, if you will, with the RCC. And we are probably 18 to 24 months away from doing that. So the remediation that I talked about is really process-oriented on our end, and I think that is going to alleviate the higher-than-average scrap that we have realized over the last six months. Operator: The next question comes from Matthew Hewitt with Craig-Hallum Capital Group. Please go ahead. Matthew Hewitt: Good afternoon. Thanks for taking the questions. Maybe first up, just so I heard you correctly, gross margins are still going to be weighed on a little bit here, first half of the year in particular. So we should be thinking somewhat similar in Q1 versus Q4? And then, you know, obviously, the Qkine partnership is unique—an opportunity to get into some new areas. Are you looking or exploring for more of those types of partnerships? Or are you still kicking the tires on potentially adding via acquisition? Thank you. Troy Wichterman: Yes, that is correct, and actually throughout the remainder of the year. As Rod mentioned, we do have inventory on hand, and it is going to take time to implement our strategies and our customers to adopt the new product format. So if you look at the full year, I would still expect in line with our guidance, as what we said. Roderick de Greef: Yes. I think it is all three of the things that I mentioned, which would be, you know, an outright targeted acquisition, a minority investment strategy, and/or a strategic collaboration like we have done with Qkine. And that is not to say that what we have done with Qkine is the final end step with them. As this relationship evolves into the future, as we understand how to sell that product better, it could very well be that things develop down the road with that particular company. Operator: The next question comes from Carl Byrnes with Northland Capital Markets. Please go ahead. Carl Byrnes: Yes, thanks for taking my question. Actually, most of my questions have been answered. I am just wondering if you are seeing any potential acquisitions that would be in the biopreservation area where the valuations have kind of come back to what would be more normalized attractive levels to pull the trigger? Thanks. Roderick de Greef: So, Carl, other than the Panthera acquisition, we keep a pretty close eye on what we consider to be potentially competitive technology in biopreservation. And while we are pretty rigorous in evaluating what is out there, nothing has come to our attention that would provide us with any sort of competitive advantage or value proposition that we do not already provide. That is why Panthera was unique, and that is why we made the move with it that we did. Carl Byrnes: Got it. Thanks. Congratulations again. Roderick de Greef: Thank you, Carl. Operator: The next question comes from Michael Okunewitch with Maxim Group. Please go ahead. Michael Okunewitch: Hey, guys. Thank you for taking my questions today. I guess I would like to ask a little about the Qkine collaboration. In particular, how comprehensive is this, and are there other commonly used cytokines and growth factors for cell and gene therapy manufacturing that might be the subject of future agreements or M&A activity? And then just to follow up on that, as you are saying that there is exclusivity on a limited number of cytokines, but is that exclusivity going both ways as in terms of who else can use CellSeal for those particular cytokines, potential distribution agreements that you may enter or any acquisition, trying to see if the exclusivity is just for you or for them to you as well. Roderick de Greef: Yes. I think the short answer is yes. The deal as it stands now is specific, from an exclusivity perspective, to certain of their cytokines that we believe are geared toward the types that are used by our key customers, as well as the pipelines that they have. So that is why it is a fairly narrow exclusivity. And we do have access to a much broader number of products on a nonexclusive basis. So, again, I would reiterate that this is the first step. We spent quite some time developing the relationship, primarily through our VP of Sales who is also located in the UK and has a history with these folks. And so I would say it is step one of a number of different ways the relationship could continue to move forward. Well, right now, it is one way for us relative to their cytokines. We have a sort of loose intent between the two parties around CellSeal, so we have to pay for that still. But I anticipate, based on discussions that we have had, that it is in their interest and our interest to widely have their products sold through with the CellSeal packaging to wherever it needs to go, or wherever they would like it to go, because that benefits us and it benefits them. And it is unique to them. We do not anticipate at this point in time entering into any agreements with other cytokine manufacturers to utilize the CellSeal vial. Michael Okunewitch: Alright. Thank you very much. I appreciate the additional color. Roderick de Greef: You bet. Operator: This concludes the question and answer session. I would like to turn the conference back over to Roderick de Greef for any closing remarks. Please go ahead. Roderick de Greef: Thank you, operator. In closing, we expect 2026 to be another strong year of revenue growth, operating margin expansion, and increased profitability. As the broader macro environment continues to evolve favorably, we remain focused on supporting our core BPM customer base, increasing adoption of our non-BPM products, and driving operational excellence across the organization. We are confident that our market leadership and business model position BioLife Solutions, Inc. to benefit from the secular trends developing across our growing yet still early-stage end markets, enabling us to deliver sustainable revenue growth, expanding profitability, and long-term shareholder value creation. Thank you for your time today. I look forward to seeing some of you at upcoming investor conferences. Operator: The conference has now concluded. Thank you for attending today's presentation. You may now disconnect. Before you buy stock in BioLife Solutions, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and BioLife Solutions wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $445,995!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,198,823!* Now, it’s worth noting Stock Advisor’s total average return is 927% — a market-crushing outperformance compared to 194% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors. See the 10 stocks » *Stock Advisor returns as of February 26, 2026. This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. BioLife (BLFS) Q4 2025 Earnings Call Transcript was originally published by The Motley Fool

Performance was primarily driven by the biopreservation media (BPM) franchise, which benefited from a shift toward later-stage and commercially approved cell and gene therapies. The company completed a multiyear strategic transformation, including the divestiture of the EVO product line, to focus on a streamlined portfolio of high-demand consumables. Commercial customers now represent approximately 50% of revenue, up from the low-40s in 2024, providing enhanced visibility and recurring revenue stability. Management attributes a decline in gross margin to a product mix shift toward bags and lower-than-anticipated bag yields during the second half of the year. Market leadership is reinforced by embedding BPM products in 16 approved therapies and approximately 80% of phase 3 clinical trials. Strategic expansion into adjacencies like cytokines via the Qkine partnership is intended to broaden the platform and increase participation in the cell therapy ecosystem. Revenue guidance of $112.5 million to $115.0 million assumes continued demand from commercial BPM customers and increased adoption of other cell processing tools. Management expects to achieve full-year positive GAAP net income for the first time in many years, driven by operating leverage and revenue growth. The cross-sell strategy aims to increase revenue per patient dose by two to three times as customers integrate broader toolsets into their workflows. Gross margins are expected to remain in the mid-60s as favorable pricing is offset by the growth of lower-margin non-BPM tools and the sell-through of high-cost bag inventory. The regulatory funnel is expected to regain momentum with up to five unique therapy approvals and several geographic expansions anticipated over the next twelve months. Bag yield issues created a 2% to 3% headwind on gross margins in late 2025; remediation involves a 90-day customer notification process and process-oriented changes. A $1.3 million sales tax true-up gain in Q4 2025 significantly impacted adjusted EBITDA margins but is considered a non-recurring benefit. The implementation of new ERP manufacturing modules in February 2025 is expected to provide a foundation for automated scaling and improved quality controls. HPL media business was flat in 2025 due to China import restrictions, though management noted these restrictions have since been abated. Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Management believes patient access is the largest constraint to adoption, noting only about 20% of eligible patients currently receive CAR-T therapies. While the REMS removal is a positive step, it is too early to parse its specific impact on the top line as it will take time to flow through to patient treatment volumes. A solution for bag yields has been identified but requires a 90-day notification period for customers. Margin benefits from higher-yield bags are not expected until Q4 2026 after the company sells through existing higher-cost finished inventory. The agreement is a long-term strategic move to enter a new product category that complements the emerging HPL product line. Revenue from the combination of cytokines and CellSeal vials is expected to begin late 2026 or early 2027 following a 6- to 9-month development cycle. Management continues to evaluate targeted acquisitions, minority investments, and collaborations but sees no current competitive technology that offers a superior value proposition to their own. The focus remains on adjacencies rather than direct competitors in the core biopreservation space. One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

Strong 2025 results: Revenue rose 29% to about $96 million, adjusted EBITDA increased to $25 million (26% of revenue), and cash plus marketable securities climbed to $120.2 million following the SAVSU divestiture. BPM remains the core growth driver: Biopreservation media accounted for roughly 85% of Q4 revenue, is embedded in 16 approved therapies, and commercial BPM customers made up nearly 50% of 2025 revenue with an expected 50–55% share in 2026. 2026 outlook and margin dynamics: Management guided revenue of $112–115 million (17–20% growth) and expects positive GAAP net income with mid‑sixties gross margins, while noting a ~2–3 point gross‑margin headwind from lower bag yields that should improve around Q4 2026. Interested in BioLife Solutions, Inc.? Here are five stocks we like better. Best Biotech Stocks to Invest in Now BioLife Solutions (NASDAQ:BLFS) reported fourth-quarter and full-year 2025 results highlighting double-digit growth, expanding profitability, and a more focused portfolio following recent divestiture activity. Management said 2025 performance reflected strength in the company’s biopreservation media (BPM) franchise and increased demand tied to commercially approved cell and gene therapy (CGT) customers, while outlining 2026 guidance calling for continued revenue growth and margin expansion. Chairman and CEO Rod de Greef said 2025 was “another strong year,” marked by portfolio repositioning and a simpler operating structure. Total revenue from continuing operations increased 29% year-over-year to about $96 million, landing “at the high end” of guidance that was raised twice in the second half of the year, according to management. → SoundHound’s New Sales Assist Agent Put Voice AI Back in the Spotlight 3 Small-Cap Medical Stocks Moving Markets Today In the fourth quarter, revenue was $24.8 million, up 20% from the prior-year period. De Greef attributed the growth primarily to continued strength in BPM, along with broad-based growth across the company’s cell processing tools portfolio. While BioLife’s gross margin declined year-over-year, the company reported improved operating leverage. De Greef said adjusted EBITDA rose to $25 million, or 26% of revenue, compared with $13 million, or 18% of revenue, in 2024. → Microsoft Is Sliding—An Insider Buy and Oversold Signals Are Changing the Setup Management emphasized the scale and consistency of the BPM franchise in Q4. De Greef said BPM accounted for approximately 85% of total quarterly revenue, and the top 20 BPM customers represented roughly 80% of BPM revenue—metrics he said were consistent with prior quarters and supported visibility into demand. BioLife also pointed to a continued shift toward later-stage and approved therapies. De Greef said commercial BPM customers represented nearly 50% of revenue in 2025, up from the “low 40s range” in 2024. In the Q&A, he said he expects commercial customers to make up roughly 50% to 55% of revenue in 2026. → AVGO Earnings Are Just Around the Corner—Here's What to Watch On market positioning, BioLife said its BPM products are embedded in 16 approved therapies and used in more than 250 relevant commercially sponsored CGT trials in the U.S., representing over 70% share. De Greef added that among more than 30 phase 3 trials, the company’s share is “approaching 80%.” CFO Troy Wichterman said adjusted gross margin in Q4 was $15.8 million, or 64%, compared with $14.0 million, or 67%, a year earlier. For full-year 2025, adjusted gross margin was $63.2 million, or 66%, compared with $51.4 million, or 69%, in 2024. Wichterman attributed the margin rate decline to mix shift toward bags, which carry lower margins than bottles, and to lower-than-anticipated bag yields in the second half of the year. De Greef later quantified the bag-yield issue as a “2 to 3-point headwind” on gross margin in the second half. Management said improving bag yields is an operational priority entering 2026, but the expected benefit will take time to materialize. De Greef said the solution requires a 90-day customer notification and that the company must sell through higher-cost bag inventory already on hand. He said the impact from improved yields is expected “right around Q4” of 2026. Separately, Wichterman said the company implemented ERP manufacturing modules in early February “with no disruption to operations,” describing the rollout as enabling more automated processes and controls across manufacturing, quality, and accounting. BioLife reported improved profitability metrics in 2025. Wichterman said adjusted operating income in Q4 was $0.9 million, compared with an adjusted operating loss of $0.2 million in the prior-year quarter. Full-year adjusted operating income was $2.9 million versus an adjusted operating loss of $2.6 million in 2024. Adjusted net income was $1.9 million in Q4, compared with an adjusted net loss of $0.1 million a year earlier. For the full year, adjusted net income was $6.3 million compared with an adjusted net loss of $2.9 million in 2024. Wichterman said the year-over-year improvements were driven primarily by higher revenue and a $1.3 million decrease in the company’s sales tax accrual, partially offset by higher R&D expense related to headcount and investments in key projects. Adjusted EBITDA was $6.9 million (28% of revenue) in Q4, up from $3.7 million (18% of revenue) in the prior-year quarter. Wichterman said a $1.3 million gain on a sales tax true-up in Q4 had an approximately 500-basis-point impact on adjusted EBITDA margin in the quarter and about 100 basis points for the full year. On liquidity, BioLife ended 2025 with $120.2 million in cash and marketable securities, up from $105.4 million at the end of 2024. Wichterman said the Q4 cash increase was primarily driven by $23.5 million in proceeds from the divestiture of SAVSU, partially offset by capital expenditures of $4.4 million, working capital usage of $2.2 million, and $2.5 million of debt payments. The company’s remaining SBA debt balance was $5 million, all short-term, which it expects to fully repay by June 2026 along with a $1.2 million balloon payment at maturity. For 2026, BioLife guided to revenue of $112 million to $115 million (also stated as $112.5 million to $115 million), implying 17% to 20% growth. Management said the outlook is based on visibility into demand forecasts from key BPM customers and is expected to be driven primarily by customers with commercially approved therapies, along with increased demand for other tools. Wichterman said the company expects GAAP and adjusted gross margin in the “mid-sixties,” with margins generally in line with 2025, supported by higher average selling prices but partially offset by product mix and higher growth rates in other cell processing tools. Management also said it expects full-year positive GAAP net income in 2026 and further expansion in adjusted EBITDA margin, while noting planned increases in R&D and sales and marketing expense to support longer-term growth. As of Feb. 19, 2026, BioLife had 48.3 million shares outstanding and 50.2 million shares on a fully diluted basis, Wichterman said. In strategic updates, de Greef discussed a recent agreement with UK-based Qkine Limited, providing exclusive distribution rights for certain cytokines and non-exclusive rights for others within the CGT market. He said the companies will also work together to package and store certain cytokines in BioLife’s CellSeal vial line, describing the effort as a long-term move rather than a major 2026 revenue driver. BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife's product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells. The company's flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies. The article "BioLife Solutions Q4 Earnings Call Highlights" was originally published by MarketBeat.